BP
ALNY icon

Ballentine Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ballentine Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
1,695
+56
+3% +$16.9K 0.01% 559
2026
Q1 		$542K Sell
1,639
-82
-5% -$27.9K 0.01% 501
2025
Q4 		$684K Buy
1,721
+60
+4% +$26.6K 0.01% 407
2025
Q3 		$757K Buy
1,661
+44
+3% +$17.9K 0.01% 386
2025
Q2 		$527K Sell
1,617
-8
-0.5% -$2.21K 0.01% 465
2025
Q1 		$439K Buy
1,625
+52
+3% +$13.4K 0.01% 487
2024
Q4 		$370K Buy
1,573
+39
+3% +$10.3K 0.01% 515
2024
Q3 		$422K Buy
1,534
+145
+10% +$37.8K 0.01% 469
2024
Q2 		$338K Buy
+1,389
New +$219K 0.01% 523
2024
Q1 		– Sell
-1,221
Closed -$234K – 742
2023
Q4 		$234K Buy
+1,221
New +$208K ﹤0.01% 584

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
PSC
Portman Square Capital London, United Kingdom $2.11B AUM 19.71% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Ballentine Partners's ALNY Position: Q2 2026 in Review

Ballentine Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 3.4% in Q2 2026, buying an estimated $16.9K and bringing the position to 1,695 shares worth $510K. The position accounts for 0.01% of the portfolio, ranked #559.

Ballentine Partners first reported a position in ALNY in Q4 2023 and has held it in 10 quarters since. The position peaked at $757K in Q3 2025. 105 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Ballentine Partners held 1,695 shares of Alnylam Pharmaceuticals worth $510K as of Q2 2026.
  • Ballentine Partners bought 56 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.9K.
  • Alnylam Pharmaceuticals made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #559 holding.
  • Ballentine Partners first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Ballentine Partners's Alnylam Pharmaceuticals position peaked at $757K in Q3 2025.
  • 105 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.